Q4 2024 Perimeter Medical Imaging AI Inc Earnings Call Transcript
Key Points
- Perimeter Medical Imaging AI Inc (PYNKF) reported a 303% increase in revenue for Q4 2024 compared to Q4 2023, driven by sales of consumables and system leases.
- The company achieved a 35% decrease in net loss for Q4 2024 compared to the same period in 2023, primarily due to higher foreign exchange gains.
- Perimeter successfully completed a pivotal clinical trial for its B-Series OCT system with ImgAssist AI 2.0, demonstrating a statistically significant reduction in patients with residual cancer during surgery.
- The company submitted a premarket approval application to the FDA for its B-Series OCT system, marking a major milestone in its regulatory process.
- Perimeter expanded its commercial presence by entering two new states, New Mexico and Tennessee, and increased the number of surgeons using its products, contributing to revenue growth.
- Operating expenses for Q4 2024 were approximately $4.7 million, indicating a high cost structure despite a decrease from the previous year.
- The company reported a net loss of approximately $3.4 million for Q4 2024, highlighting ongoing financial challenges.
- Cash used in operating activities remained high at approximately $14.7 million for the year ending December 31, 2024, indicating significant cash burn.
- Perimeter's cash and cash equivalents were approximately $6.2 million as of December 31, 2024, suggesting a need for additional funding to support growth strategies.
- The company faces uncertainties related to the timing of FDA approval for its B-Series OCT system, which could impact its commercialization plans.
Good afternoon, ladies and gentlemen, and welcome to the Perimeter Medical Q4 2024 conference call. (Operator Instructions) This call is being recorded on Wednesday, March 26, 2025. I would now like to turn the conference over to Stephen Kilmer, Investor Relations. Thank you. Please go ahead.
Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws. These may include statements regarding the future financial position, business strategy and strategic goals, commercial activities and timing, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, the potential benefits of our products, including Perimeter S-Series OCT, Perimeter B-Series OCT and Perimeter ImgAssist, Perimeter's ability to broaden its user base and expected approval of its proprietary AI, expectations regarding new
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
